Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Banales, J. M. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261–280 (2016).

pubmed: 27095655

Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95–111 (2018).

pubmed: 28994423

Munoz-Garrido, P. & Rodrigues, P. M. The jigsaw of dual hepatocellular-intrahepatic cholangiocarcinoma tumours. Nat. Rev. Gastroenterol. Hepatol. 16, 653–655 (2019).

pubmed: 31296968

Brunt, E. et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68, 113–126 (2018).

pubmed: 29360137 pmcid: 6340292

Khan, A. S. & Dageforde, L. A. Cholangiocarcinoma. Surg. Clin. North. Am. 99, 315–335 (2019).

pubmed: 30846037

DeOliveira, M. L. et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245, 755–762 (2007).

pubmed: 17457168 pmcid: 1877058

Nakeeb, A. et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224, 463–473 (1996).

pubmed: 8857851 pmcid: 1235406

Andersen, J. B. et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142, 1021–1031.e15 (2012).

Bertuccio, P. et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J. Hepatol. 71, 104–114 (2019).

pubmed: 30910538

Lindner, P., Rizell, M. & Hafstrom, L. The impact of changed strategies for patients with cholangiocarcinoma in this millenium. HPB Surg. 2015, 736049 (2015).

pubmed: 25788760 pmcid: 4348584

Kamsa-Ard, S. et al. Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand from 1989 through 2013: a population-based cancer registry study. J. Epidemiol. 29, 197–204 (2019).

pubmed: 30078813 pmcid: 6445798

Strijker, M. et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 58, 1048–1055 (2019).

pubmed: 30907207

Alabraba, E. et al. Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. Eur. J. Surg. Oncol. 45, 1660–1667 (2019).

pubmed: 31014988

Groot Koerkamp, B. et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J. Am. Coll. Surg. 221, 1041–1049 (2015).

pubmed: 26454735 pmcid: 4736142

Komaya, K. et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery 163, 732–738 (2018).

pubmed: 29336813

Cambridge, W. A. et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma. Ann. Surg. https://doi.org/10.1097/SLA.0000000000003801 (2020).

doi: 10.1097/SLA.0000000000003801

Spolverato, G. et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann. Surg. Oncol. 23, 235–243 (2016).

pubmed: 26059651

Yao, K. J., Jabbour, S., Parekh, N., Lin, Y. & Moss, R. A. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 16, 117 (2016).

pubmed: 27655244 pmcid: 5031355

Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39 (Suppl. 1), 19–31 (2019).

pubmed: 30851228

Bosman, F. T., Carneiro, F., Hruban, R. & Theise N. WHO Classification of Tumours: Digestive System Tumours 5th edn Vol. 1 (IARC, 2019).

Antwi, S. O., Mousa, O. Y. & Patel, T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995–2014. Ann. Hepatol. 17, 604–614 (2018).

pubmed: 29893702

Ransome, E. et al. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005–2014. J. Gastrointest. Oncol. 10, 339–347 (2019).

pubmed: 31032103 pmcid: 6465498

Uhlig, J. et al. Intrahepatic cholangiocarcinoma: socioeconomic discrepancies, contemporary treatment approaches and survival trends from the National Cancer Database. Ann. Surg. Oncol. 26, 1993–2000 (2019).

pubmed: 30693451

Sapisochin, G. et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 64, 1178–1188 (2016).

pubmed: 27481548

Alberts, R. et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut 67, 1517–1524 (2018).

pubmed: 28779025

Xue, R. et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35, 932–947.e8 (2019).

pubmed: 31130341

Saha, S. K., Zhu, A. X., Fuchs, C. S. & Brooks, G. A. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21, 594–599 (2016).

pubmed: 4861366 pmcid: 4861366

Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60, 1268–1289 (2014).

pubmed: 24681130

Bray, F. et al. (eds) Cancer incidence in five continents (CI5) volume XI. IARC https://ci5.iarc.fr (2017).

Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D. & Khan, S. A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J. Hepatol. 72, 95–103 (2020).

pubmed: 31536748

Xiong, J. et al. Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis. Cancer Manag. Res. 10, 4095–4104 (2018).

pubmed: 30323665 pmcid: 6173493

Burr, N. E. et al. Aspirin may prevent cholangiocarcinoma: a case-control study from the United Kingdom. Dig. Dis. Sci. 59, 1567–1572 (2014).

pubmed: 24535250

Choi, J. et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology 64, 785–796 (2016).

pubmed: 26940227 pmcid: 5995727

Liu, Z. et al. Statin use and reduced risk of biliary tract cancers in the UK clinical practice research datalink. Gut 68, 1458–1464 (2019).

pubmed: 30448774

Peng, Y. C. et al. Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. Br. J. Clin. Pharmacol. 80, 755–761 (2015).

pubmed: 25808421 pmcid: 4594712

Jackson, S. S. et al. Association between aspirin use and biliary tract cancer survival. JAMA Oncol. 5, 1802–1804 (2019).

pmcid: 6802421

Lee, D. H. & Lee, J. M. Primary malignant tumours in the non-cirrhotic liver. Eur. J. Radiol. 95, 349–361 (2017).

pubmed: 28987692

Nakanuma, Y. et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2, 419–427 (2010).

pubmed: 21191517 pmcid: 3010511

Deoliveira, M. L. et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53, 1363–1371 (2011).

pubmed: 21480336

Nakanuma, Y. & Kakuda, Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract. Res. Clin. Gastroenterol. 29, 277–293 (2015).

pubmed: 25966428

Kendall, T. et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 39 (Suppl. 1), 7–18 (2019).

pubmed: 30882996

Aishima, S. et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am. J. Surg. Pathol. 31, 1059–1067 (2007).

pubmed: 17592273

Akita, M. et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod. Pathol. 30, 986–997 (2017).

pubmed: 28338651

Liau, J. Y. et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 27, 1163–1173 (2014).

pubmed: 24406866

Hayashi, A. et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 40, 1021–1030 (2016).

pubmed: 27259014

Komuta, M. et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 55, 1876–1888 (2012).

pubmed: 22271564

Cardinale, V. et al. Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. Hepatology 55, 2041–2042 (2012).

pubmed: 22262236

Igarashi, S. et al. Participation of peribiliary glands in biliary tract pathophysiologies. World J. Hepatol. 5, 425–432 (2013).

pubmed: 24023981 pmcid: 3767841

Carpino, G. et al. Neoplastic transformation of the peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis. Hepatology 69, 622–638 (2019).

pubmed: 30102768

Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427–1434 (2014).

pubmed: 24122810

Borger, D. R. et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17, 72–79 (2012).

pubmed: 22180306

Graham, R. P. et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 45, 1630–1638 (2014).

pubmed: 24837095

Kipp, B. R. et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum. Pathol. 43, 1552–1558 (2012).

pubmed: 22503487

Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin. Cancer Res. 24, 4154–4161 (2018).

pubmed: 29848569 pmcid: 6642361

Ge, X. et al. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol. Rep. 30, 448–454 (2013).

pubmed: 23619566

Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003–1010 (2015).

pubmed: 26258846

Wang, P. et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32, 3091–3100 (2013).

pubmed: 22824796

Yachida, S. et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell 29, 229–240 (2016).

pubmed: 26806338 pmcid: 5503303

Visvader, J. E. Cells of origin in cancer. Nature 469, 314–322 (2011).

pubmed: 21248838

Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669–680 (2018).

pubmed: 30228301

Sutherland, K. D. & Visvader, J. E. Cellular mechanisms underlying intertumoral heterogeneity. Trends Cancer 1, 15–23 (2015).

pubmed: 28741558

Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).

pubmed: 5957518 pmcid: 5957518

Coulouarn, C. et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis 33, 1791–1796 (2012).

pubmed: 22696594

Moeini, A. et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J. Hepatol. 66, 952–961 (2017).

pubmed: 28126467

Cardinale, V. et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am. J. Pathol. 185, 1724–1739 (2015).

pubmed: 25892683 pmcid: 4450332

Lanzoni, G., Cardinale, V. & Carpino, G. The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: a new reference frame for disease and regeneration. Hepatology 64, 277–286 (2016).

pubmed: 26524612

Bragazzi, M. C. et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann. Gastroenterol. 31, 42–55 (2018).

pubmed: 29333066

Cardinale, V., Carpino, G., Reid, L., Gaudio, E. & Alvaro, D. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J. Gastrointest. Oncol. 4, 94–102 (2012).

pubmed: 22645632 pmcid: 3360107

Komuta, M. et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47, 1544–1556 (2008).

pubmed: 18393293

Lee, J. S. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410–416 (2006).

pubmed: 16532004

Sia, D., Villanueva, A., Friedman, S. L. & Llovet, J. M. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 152, 745–761 (2017).

Woo, H. G. et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 70, 3034–3041 (2010).

pubmed: 20395200 pmcid: 3498758

Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78–81 (2015).

pubmed: 25554788 pmcid: 25554788

Zhu, L. et al. Multi-organ mapping of cancer risk. Cell 166, 1132–1146.e7 (2016).

pubmed: 27565343 pmcid: 5067024

Carpino, G. et al. Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis. J. Hepatol. 63, 1220–1228 (2015).

pubmed: 26119688

Vicent, S. et al. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver Int. 39 (Suppl. 1), 79–97 (2019).

pubmed: 30851232

Dill, M. T. et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 57, 1607–1619 (2013).

pubmed: 23175466

Guest, R. V. et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 74, 1005–1010 (2014).

pubmed: 24310400

Sekiya, S. & Suzuki, A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914–3918 (2012).

pubmed: 23023701 pmcid: 3484442

Fan, B. et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 122, 2911–2915 (2012).

pubmed: 22797301 pmcid: 3408746

Wang, J. et al. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene 37, 3229–3242 (2018).

pubmed: 29545603 pmcid: 6002343

Lu, W. Y. et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat. Cell Biol. 17, 971–983 (2015).

pubmed: 26192438 pmcid: 4612439

Raven, A. et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature 547, 350–354 (2017).

pubmed: 28700576 pmcid: 5522613

Rios, A. C., Fu, N. Y., Cursons, J., Lindeman, G. J. & Visvader, J. E. The complexities and caveats of lineage tracing in the mammary gland. Breast Cancer Res. 18, 116 (2016).

pubmed: 27887631 pmcid: 5124259

Tarlow, B. D., Finegold, M. J. & Grompe, M. Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury. Hepatology 60, 278–289 (2014).

pubmed: 24700457 pmcid: 4077948

Lemaigre, F. P. Determining the fate of hepatic cells by lineage tracing: facts and pitfalls. Hepatology 61, 2100–2103 (2015).

pubmed: 25503476

De Minicis, S. et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig. Liver Dis. 45, 450–459 (2013).

pubmed: 23177172

Alvaro, D. et al. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver Disease. Dig. Liver Dis. 43, 60–65 (2011).

pubmed: 20580332

Wildner, D. et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients – early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med. 36, 132–139 (2015).

pubmed: 25812115

Sirica, A. E. et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology 69, 1803–1815 (2019).

pubmed: 30251463 pmcid: 6433548

Joo, I., Lee, J. M. & Yoon, J. H. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 288, 7–13 (2018).

pubmed: 29869969

Jhaveri, K. S. & Hosseini-Nik, H. MRI of cholangiocarcinoma. J. Magn. Reson. Imaging 42, 1165–1179 (2015).

pubmed: 25447417

Rimola, J. et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50, 791–798 (2009).

pubmed: 19610049

Galassi, M. et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int. 33, 771–779 (2013).

pubmed: 23445369

Chernyak, V. et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289, 816–830 (2018).

pubmed: 30251931 pmcid: 6677371

Choi, S. H. et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 282, 771–781 (2017).

pubmed: 27797675

Vilana, R. et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51, 2020–2029 (2010).

pubmed: 20512990

Terzi, E. et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J. Hepatol. 68, 485–492 (2018).

pubmed: 29133247

American College of Radiology. CEUS LI-RADS v2017. ACR https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CEUS-LI-RADS-v2017 (2017).

Lamarca, A. et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J. Hepatol. 71, 115–129 (2019).

pubmed: 30797051

Hamilton, S. R. A. et al. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System 3rd edn Vol. 2 (IARC, 2000).

Ishak, K. G., Goodman, Z. D. & Stocker, J. T. Atlas of Tumor Pathology: Tumors of the Liver and Intrahepatic Bile Ducts (Armed Forces Institute of Pathology, 2001).

Amin, M. B. et al. AJCC Cancer Staging Manual (Springer, 2017).

Forner, A. et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 39 (Suppl. 1), 98–107 (2019).

pubmed: 30831002

Spolverato, G. et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J. Surg. Oncol. 115, 696–703 (2017).

pubmed: 28194791

Kang, S. H. et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 25, 240–248 (2018).

pubmed: 29450978

Lamarca, A. et al. Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging [abstract 731P]. Ann. Oncol. 30 (Suppl. 5), v280–v281 (2019).

Sapisochin, G. et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am. J. Transpl. 14, 660–667 (2014).

Chaiteerakij, R. et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am. J. Gastroenterol. 109, 1881–1890 (2014).

pubmed: 25384902 pmcid: 4341961

Sia, D. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144, 829–840 (2013).

pubmed: 3624083 pmcid: 3624083

Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).

pubmed: 23770567 pmcid: 3919509

Borad, M. J. et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 10, e1004135 (2014).

pubmed: 24550739 pmcid: 3923676

Ross, J. S. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19, 235–242 (2014).

pubmed: 24563076 pmcid: 3958461

Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636–647 (2013).

pubmed: 23558953 pmcid: 3694764

Sia, D. et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 6, 6087 (2015).

pubmed: 25608663

Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116–1135 (2017).

pubmed: 28667006 pmcid: 5628134

Chan-On, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474–1478 (2013).

pubmed: 24185513

Ong, C. K. et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 44, 690–693 (2012).

pubmed: 22561520

Nepal, C. et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 68, 949–963 (2018).

pubmed: 29278425 pmcid: 6599967

Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).

pubmed: 25526346

Farshidfar, F. et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 18, 2780–2794 (2017).

pubmed: 28297679 pmcid: 5493145

O’Rourke, C. J., Munoz-Garrido, P., Aguayo, E. L. & Andersen, J. B. Epigenome dysregulation in cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1423–1434 (2018).

pubmed: 28645654

Javle, M. et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36, 276–282 (2018).

pubmed: 29182496

Mazzaferro, V. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120, 165–171 (2019).

pubmed: 30420614

Braconi, C. et al. Molecular perturbations in cholangiocarcinoma: is it time for precision medicine? Liver Int. 39 (Suppl. 1), 32–42 (2019).

pubmed: 30829432

Melum, E. et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat. Genet. 43, 17–19 (2011).

pubmed: 21151127

Gingras, M. C. et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 14, 907–919 (2016).

pubmed: 26804919 pmcid: 4982376

Abou-Alfa, G. K. et al. ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann. Oncol. 30 (Suppl. 5), v851–v934 (2019).

Saha, S. K. et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016).

pubmed: 27231123 pmcid: 5458737

Lampis, A. et al. MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology 154, 1066–1079.e5 (2018).

pubmed: 29113809 pmcid: 5863695

O’Rourke, C. J., Lafuente-Barquero, J. & Andersen, J. B. Epigenome remodeling in cholangiocarcinoma. Trends Cancer 5, 335–350 (2019).

pubmed: 31208696

Merino-Azpitarte, M. et al. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J. Hepatol. 67, 72–83 (2017).

pubmed: 28237397 pmcid: 5502751

Goeppert, B. et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 59, 544–554 (2014).

pubmed: 24002901

Easwaran, H. et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 22, 837–849 (2012).

pubmed: 22391556 pmcid: 3337430

Bernhart, S. H. et al. Changes of bivalent chromatin coincide with increased expression of developmental genes in cancer. Sci. Rep. 6, 37393 (2016).

pubmed: 27876760 pmcid: 5120258

Goeppert, B. et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology 69, 2091–2106 (2019).

pubmed: 30615206 pmcid: 6594081

Morine, Y. et al. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery 151, 412–419 (2012).

pubmed: 21982637

Salati, M. & Braconi, C. Noncoding RNA in cholangiocarcinoma. Semin. Liver Dis. 39, 13–25 (2019).

pubmed: 30536290

Gradilone, S. A., O’Hara, S. P., Masyuk, T. V., Pisarello, M. J. & LaRusso, N. F. MicroRNAs and benign biliary tract diseases. Semin. Liver Dis. 35, 26–35 (2015).

pubmed: 25632932 pmcid: 4413449

Erice, O. et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1335–1344 (2018).

pubmed: 28916388

Mansini, A. P. et al. MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology 68, 561–573 (2018).

pubmed: 29406621 pmcid: 6078832

Carotenuto, P. et al. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut 66, 1268–1277 (2017).

pubmed: 27618837

Andersen, J. B. & Thorgeirsson, S. S. Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities. Gastroenterology 144, 687–690 (2013).

pubmed: 23462122

Isomoto, H. et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42, 1329–1338 (2005).

pubmed: 16317687

Wehbe, H., Henson, R., Meng, F., Mize-Berge, J. & Patel, T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 66, 10517–10524 (2006).

pubmed: 17079474

Sirica, A. E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 14, 7033–7058 (2008).

pubmed: 19084911 pmcid: 2776834

Lozano, E. et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol. Cancer Res. 12, 91–100 (2014).

pubmed: 24255171

Brivio, S., Cadamuro, M., Strazzabosco, M. & Fabris, L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J. Hepatol. 9, 455–468 (2017).

pubmed: 28396716 pmcid: 5368623

Moeini, A., Sia, D., Bardeesy, N., Mazzaferro, V. & Llovet, J. M. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin. Cancer Res. 22, 291–300 (2016).

pubmed: 26405193

Gu, T. L. et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 (2011).

pubmed: 21253578 pmcid: 3017127

Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470–1473 (2013).

pubmed: 24185509 pmcid: 4013720

Xue, T. C., Zhang, B. H., Ye, S. L. & Ren, Z. G. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis. Tumour Biol. 36, 5891–5899 (2015).

pubmed: 25712376

Turnpenny, P. D. & Ellard, S. Alagille syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 20, 251–257 (2012).

pubmed: 21934706

Geisler, F. & Strazzabosco, M. Emerging roles of Notch signaling in liver disease. Hepatology 61, 382–392 (2015).

pubmed: 24930574

Wu, W. R. et al. Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma. Int. J. Clin. Exp. Pathol. 7, 3272–3279 (2014).

pubmed: 25031748 pmcid: 4097216

Wu, W. R. et al. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. Oncol. Rep. 31, 2515–2524 (2014).

pubmed: 24700253

Aoki, S. et al. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties. BMC Cancer 16, 854 (2016).

pubmed: 27821106 pmcid: 5100105

Zender, S. et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23, 784–795 (2013).

pubmed: 23727022

Huntzicker, E. G. et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology 61, 942–952 (2015).

pubmed: 25311838 pmcid: 4447303

Guest, R. V. et al. Notch3 drives development and progression of cholangiocarcinoma. Proc. Natl Acad. Sci. USA 113, 12250–12255 (2016).

pubmed: 27791012

Cigliano, A., Wang, J., Chen, X. & Calvisi, D. F. Role of the Notch signaling in cholangiocarcinoma. Expert Opin. Ther. Targets 21, 471–483 (2017).

pubmed: 28326864

Loilome, W. et al. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells. Tumour Biol. 35, 5357–5367 (2014).

pubmed: 24549785 pmcid: 4862210

Boulter, L. et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J. Clin. Invest. 125, 1269–1285 (2015).

pubmed: 25689248 pmcid: 4362247

Perugorria, M. J. et al. Wnt-β-catenin signalling in liver development, health and disease. Nat. Rev. Gastroenterol. Hepatol. 16, 121–136 (2019).

pubmed: 30451972

Pan, D. Hippo signaling in organ size control. Genes Dev. 21, 886–897 (2007).

pubmed: 17437995

Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179–183 (2011).

Li, H. et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 32, 38–47 (2012).

pubmed: 22098159

Tao, J. et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147, 690–701 (2014).

pubmed: 24837480 pmcid: 4143445

Pei, T. et al. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget 6, 17206–17220 (2015).

pubmed: 26015398 pmcid: 4627302

Smoot, R. L. et al. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J. Cell Biochem. 119, 824–836 (2018).

pubmed: 28661054

Rizvi, S. et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J. Biol. Chem. 291, 8031–8047 (2016).

pubmed: 26826125 pmcid: 4825008

Sugihara, T., Isomoto, H., Gores, G. & Smoot, R. YAP and the Hippo pathway in cholangiocarcinoma. J. Gastroenterol. 54, 485–491 (2019).

pubmed: 30815737 pmcid: 6536462

Chang, L. et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature 563, 265–269 (2018).

pubmed: 30401838

Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).

Sulpice, L. et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 58, 1992–2000 (2013).

pubmed: 23775819

Claperon, A. et al. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 58, 2001–2011 (2013).

pubmed: 23787814

Claperon, A. et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J. Hepatol. 61, 325–332 (2014).

pubmed: 24704591

Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).

pubmed: 30459476

Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212–226 (2019).

pubmed: 30594349

Puisieux, A., Brabletz, T. & Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 16, 488–494 (2014).

pubmed: 24875735

Vaquero, J. et al. Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks. J. Hepatol. 66, 424–441 (2017).

pubmed: 27686679

Goossens, S., Vandamme, N., Van Vlierberghe, P. & Berx, G. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim. Biophys. Acta Rev. Cancer 1868, 584–591 (2017).

pubmed: 28669750

Baulida, J. Epithelial-to-mesenchymal transition transcription factors in cancer-associated fibroblasts. Mol. Oncol. 11, 847–859 (2017).

pubmed: 28544627 pmcid: 5496490

Findlay, V. J., Wang, C., Watson, D. K. & Camp, E. R. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 21, 181–187 (2014).

pubmed: 24787239 pmcid: 4041800

Cadamuro, M. et al. Autocrine and paracrine mechanisms promoting chemoresistance in cholangiocarcinoma. Int. J. Mol. Sci. 18, 149 (2017).

pmcid: 5297782

Correnti, M. & Raggi, C. Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget 8, 7094–7115 (2017).

pubmed: 27738343

Raggi, C. et al. Dysregulation of iron metabolism in cholangiocarcinoma stem-like cells. Sci. Rep. 7, 17667 (2017).

pubmed: 29247214 pmcid: 5732280

Raggi, C. et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J. Hepatol. 66, 102–115 (2017).

pubmed: 27593106

Raggi, C., Invernizzi, P. & Andersen, J. B. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J. Hepatol. 62, 198–207 (2015).

pubmed: 25220250

Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495 (2009).

pubmed: 19935649

Oishi, N. et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 56, 1792–1803 (2012).

pubmed: 22707408 pmcid: 3458130

Shuang, Z. Y. et al. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett. 354, 320–328 (2014).

pubmed: 25194504

Noman, M. Z. et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 6, e1263412 (2017).

pubmed: 28197390 pmcid: 5283623

Sirica, A. E. & Gores, G. J. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 59, 2397–2402 (2014).

pubmed: 24123296 pmcid: 3975806

Lorenzini, S. et al. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut 59, 645–654 (2010).

pubmed: 20427399 pmcid: 3034133

Tamma, R. et al. Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. Eur. J. Clin. Invest. 49, e13087 (2019).

pubmed: 30767196

Govaere, O. et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J. Hepatol. 64, 609–617 (2016).

pubmed: 26592953 pmcid: 26592953

Szendroi, M. & Lapis, K. Distribution of fibronectin and laminin in human liver tumors. J. Cancer Res. Clin. Oncol. 109, 60–64 (1985).

pubmed: 2982880

Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).

Chuaysri, C. et al. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 21, 957–969 (2009).

pubmed: 19287994

LeBleu, V. S. & Kalluri, R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis. Model. Mech. 11, dmm029447 (2018).

pubmed: 5963854 pmcid: 5963854

Itou, R. A. et al. Immunohistochemical characterization of cancer-associated fibroblasts at the primary sites and in the metastatic lymph nodes of human intrahepatic cholangiocarcinoma. Hum. Pathol. 83, 77–89 (2019).

pubmed: 30172911

Cadamuro, M. et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 58, 1042–1053 (2013).

pubmed: 23505219 pmcid: 3732815

Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017).

pubmed: 28487545

Manzanares, M. A. et al. Transforming growth factors α and β are essential for modeling cholangiocarcinoma desmoplasia and progression in a three-dimensional organotypic culture model. Am. J. Pathol. 187, 1068–1092 (2017).

pubmed: 28315313 pmcid: 5417049

Ling, H. et al. Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One 8, e54499 (2013).

pubmed: 23349909 pmcid: 3547926

El Khatib, M. et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 57, 1035–1045 (2013).

pubmed: 23172661

Ziani, L., Chouaib, S. & Thiery, J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front. Immunol. 9, 414 (2018).

pubmed: 29545811 pmcid: 5837994

Cadamuro, M. et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J. Hepatol. 70, 700–709 (2019).

pubmed: 30553841

Fabris, L. et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 39 (Suppl. 1), 63–78 (2019).

pubmed: 30907492

Utispan, K. et al. Periostin activates integrin α5β1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int. J. Oncol. 41, 1110–1118 (2012).

pubmed: 22735632

Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP/TAZ at the roots of cancer. Cancer Cell 29, 783–803 (2016).

pubmed: 27300434 pmcid: 6186419

Mertens, J. C. et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 73, 897–907 (2013).

pubmed: 23221385

Woo, S. R., Corrales, L. & Gajewski, T. F. Innate immune recognition of cancer. Annu. Rev. Immunol. 33, 445–474 (2015).

pubmed: 25622193

Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).

pubmed: 5998822 pmcid: 5998822

Atanasov, G. et al. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer 15, 790 (2015).

pubmed: 26497197 pmcid: 4620011

Hasita, H. et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 101, 1913–1919 (2010).

pubmed: 20545696

Yang, X. et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76, 4124–4135 (2016).

pubmed: 27216177

Takagi, S. et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum. Pathol. 35, 881–886 (2004).

pubmed: 15257553

Bjorkstrom, N. K., Ljunggren, H. G. & Michaelsson, J. Emerging insights into natural killer cells in human peripheral tissues. Nat. Rev. Immunol. 16, 310–320 (2016).

pubmed: 27121652

Morisaki, T. et al. Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Res. 32, 2249–2256 (2012).

pubmed: 22641659

Jung, I. H. et al. In vivo study of natural killer (NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse model. Vivo 32, 771–781 (2018).

Goeppert, B. et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 109, 2665–2674 (2013).

pubmed: 24136146 pmcid: 3833207

Kasper, H. U., Drebber, U., Stippel, D. L., Dienes, H. P. & Gillessen, A. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma. World J. Gastroenterol. 15, 5053–5057 (2009).

pubmed: 19859998 pmcid: 2768884

Lim, Y. J. et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother. Oncol. 117, 165–170 (2015).

pubmed: 26235847

Miura, T. et al. Prognostic impact of CD163

pubmed: 28011489

Oshikiri, T. et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J. Surg. Oncol. 84, 224–228 (2003).

pubmed: 14756433

Fontugne, J. et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8, 24644–24651 (2017).

pubmed: 28445951 pmcid: 5421876

Gani, F. et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 23, 2610–2617 (2016).

pubmed: 27012989

Ueno, M. et al. Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase 2 KEYNOTE-158 study. Ann. Oncol. 29 (Suppl. 8), viii205–viii270 (2018).

Silva, V. W. et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin. Clin. Oncol. 5, 62 (2016).

pubmed: 27829276

Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

pubmed: 5576142 pmcid: 5576142

Zabron, A., Edwards, R. J. & Khan, S. A. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis. Model. Mech. 6, 281–292 (2013).

pubmed: 23520144 pmcid: 3597011

Tepsiri, N. et al. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J. Gastroenterol. 11, 2748–2753 (2005).

pubmed: 15884115 pmcid: 4305909

Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).

pubmed: 23839242 pmcid: 3715866

Massani, M. et al. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Oncol. Rep. 30, 1143–1148 (2013).

pubmed: 23807641

Miserocchi, G. et al. Management and potentialities of primary cancer cultures in preclinical and translational studies. J. Transl. Med. 15, 229 (2017).

pubmed: 29116016 pmcid: 5688825

Tabibian, J. H. et al. Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab. Invest. 94, 1126–1133 (2014).

pubmed: 25046437 pmcid: 4184949

Arbelaiz, A. et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 66, 1125–1143 (2017).

pubmed: 28555885

Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4, 309–324 (2009).

pubmed: 19214182 pmcid: 19214182

Nath, S. & Devi, G. R. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol. Ther. 163, 94–108 (2016).

pubmed: 27063403 pmcid: 4961208

Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424–1435 (2017).

pubmed: 29131160 pmcid: 5722201

Nuciforo, S. et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 24, 1363–1376 (2018).

pubmed: 30067989 pmcid: 6088153

Lau, H. C. H. et al. Organoid models of gastrointestinal cancers in basic and translational research. Nat. Rev. Gastroenterol. Hepatol. 17, 203–222 (2020).

pubmed: 32099092

Saito, Y. et al. Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Sci. Rep. 8, 2821 (2018).

pubmed: 29434290 pmcid: 5809480

Saborowski, A. et al. Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro. Hepatol. Commun. 3, 423–436 (2019).

pubmed: 30859153 pmcid: 6396372

Chen, X. & Calvisi, D. F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am. J. Pathol. 184, 912–923 (2014).

pubmed: 24480331 pmcid: 3969989

Loeuillard, E., Fischbach, S. R., Gores, G. J. & Rizvi, S. Animal models of cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 982–992 (2019).

pubmed: 29627364

Mariotti, V. et al. Animal models of cholestasis: an update on inflammatory cholangiopathies. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 954–964 (2019).

pubmed: 30398152

Macias, R. I. R. et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1468–1477 (2018).

pubmed: 28782657

Olaizola, P. et al. MicroRNAs and extracellular vesicles in cholangiopathies. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1293–1307 (2018).

pubmed: 28711597

Esparza-Baquer, A., Labiano, I., Bujanda, L., Perugorria, M. J. & Banales, J. M. MicroRNAs in cholangiopathies: potential diagnostic and therapeutic tools. Clin. Res. Hepatol. Gastroenterol. 40, 15–27 (2016).

pubmed: 26774196

Andersen, R. F. & Jakobsen, A. Screening for circulating RAS/RAF mutations by multiplex digital PCR. Clin. Chim. Acta 458, 138–143 (2016).

pubmed: 27181912

Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).

pubmed: 28034880

Liang, Z., Liu, X., Zhang, Q., Wang, C. & Zhao, Y. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig. Liver Dis. 48, 1227–1232 (2016).

pubmed: 27476468

Zhou, J., Liu, Z., Yang, S. & Li, X. Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 156–162 (2017).

pubmed: 27939910

Shigehara, K. et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6, e23584 (2011).

pubmed: 21858175 pmcid: 3157401

Voigtlander, T. et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One 10, e0139305 (2015).

pubmed: 26431155 pmcid: 4591993

Wang, L. J. et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6, 5932–5946 (2015).

pubmed: 4467412 pmcid: 4467412

Correa-Gallego, C. et al. Circulating plasma levels of microRNA-21 and microRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma. PLoS One 11, e0163699 (2016).

pubmed: 27685844 pmcid: 5042503

Liu, C. H. et al. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. J. Cancer Res. Ther. 14, 220–225 (2018).

pubmed: 29516989

Afonso, M. B., Rodrigues, P. M., Simao, A. L. & Castro, R. E. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J. Clin. Med. 5, 30 (2016).

pmcid: 4810101

Wang, Y. et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 533, 389–397 (2014).

pubmed: 24076132

Wu, X. et al. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma. Tumour Biol. 37, 15019–15029 (2016).

pubmed: 27658773

Silakit, R. et al. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator. J. Hepatobiliary Pancreat. Sci. 21, 864–872 (2014).

pubmed: 25131257

Plieskatt, J. et al. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma. BMC Cancer 15, 309 (2015).

pubmed: 25903557 pmcid: 4417245

Wang, L. J. et al. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget 6, 18631–18640 (2015).

pubmed: 26087181 pmcid: 4621915

Wang, S. et al. Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma. Oncol. Rep. 33, 819–825 (2015).

pubmed: 25482320

Bernuzzi, F. et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin. Exp. Immunol. 185, 61–71 (2016).

pubmed: 26864161 pmcid: 4908296

Cheng, Q. et al. Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma. Sci. Rep. 5, 16103 (2015).

pubmed: 26534789 pmcid: 4632041

Huang, L. et al. Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma. Dig. Dis. Sci. 60, 1273–1283 (2015).

pubmed: 25487191

Uenishi, T. et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 15, 583–589 (2008).

pubmed: 17955299

Leelawat, K., Sakchinabut, S., Narong, S. & Wannaprasert, J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 9, 30 (2009).

pubmed: 19405942 pmcid: 2680894

Leelawat, K., Narong, S., Wannaprasert, J. & Ratanashu-ek, T. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J. Gastroenterol. 16, 4697–4703 (2010).

pubmed: 20872971 pmcid: 2951521

Loosen, S. H. et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J. Hepatol. 67, 749–757 (2017).

pubmed: 28668580

Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H. & Gores, G. J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128, 2054–2065 (2005).

pubmed: 15940637

Cheon, Y. K. et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am. J. Gastroenterol. 102, 2164–2170 (2007).

pubmed: 17617204

Onsurathum, S. et al. Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma. Tumour Biol. 40, 1010428318767195 (2018).

pubmed: 29629840

Shi, R. Y. et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer 119, 993–1003 (2013).

pubmed: 23132676

Xu, H. et al. Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology 55, 2000–2004 (2008).

pubmed: 19260467

Shen, J. et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS One 7, e47476 (2012).

pubmed: 23118872 pmcid: 3485295

Thuwajit, C. et al. Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis. Oncol. Lett. 14, 623–634 (2017).

pubmed: 28693214 pmcid: 5494708

Park, J. Y. et al. Bile acid analysis in biliary tract cancer. Yonsei Med. J. 47, 817–825 (2006).

pubmed: 17191311 pmcid: 2687822

Albiin, N. et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 49, 855–862 (2008).

pubmed: 18608012

Nagana Gowda, G. A., Shanaiah, N., Cooper, A., Maluccio, M. & Raftery, D. Visualization of bile homeostasis using (1)H-NMR spectroscopy as a route for assessing liver cancer. Lipids 44, 27–35 (2009).

pubmed: 18982376

Sharif, A. W. et al. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB 12, 396–402 (2010).

pubmed: 20662790 pmcid: 3028580

Satriano, L., Lewinska, M., Rodrigues, P. M., Banales, J. M. & Andersen, J. B. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat. Rev. Gastroenterol. Hepatol. 16, 748–766 (2019).

pubmed: 31666728

Liang, Q. et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. Mol. Biosyst. 12, 334–340 (2016).

pubmed: 26646623

Banales, J. M. et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology 70, 547–562 (2019).

pubmed: 30325540 pmcid: 6767196

Severino, V. et al. Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology 153, e498 (2017).

Al Ustwani, O., Iancu, D., Yacoub, R. & Iyer, R. Detection of circulating tumor cells in cancers of biliary origin. J. Gastrointest. Oncol. 3, 97–104 (2012).

pubmed: 22811877 pmcid: 3397649

Yang, J. D. et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology 63, 148–158 (2016).

pubmed: 26096702

Valle, J. W. et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 16, 967–978 (2015).

pubmed: 26179201 pmcid: 4648082

Ruys, A. T. et al. Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann. Surg. Oncol. 21, 487–500 (2014).

pubmed: 24081803

Chusorn, P. et al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol. 34, 1579–1588 (2013).

pubmed: 23417858

Valle, J. W. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v28–v37 (2016).

pubmed: 27664259

van Vugt, J. L. A. et al. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. HPB 20, 83–92 (2018).

pubmed: 28958483

Doussot, A. et al. Outcomes after resection of intrahepatic cholangiocarcinoma: external validation and comparison of prognostic models. J. Am. Coll. Surg. 221, 452–461 (2015).

pubmed: 26206643 pmcid: 4784264

Weber, S. M. et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB 17, 669–680 (2015).

pubmed: 26172134 pmcid: 4527852

Coelen, R. J. S. et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol. Hepatol. 3, 681–690 (2018).

pubmed: 30122355

Kawashima, H. et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications. Ann. Surg. 257, 121–127 (2013).

pubmed: 22895398

Bird, N. et al. Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma. Br. J. Surg. 104, 418–425 (2017).

pubmed: 27861766

Farges, O. et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br. J. Surg. 100, 274–283 (2013).

pubmed: 23124720

Nuzzo, G. et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch. Surg. 147, 26–34 (2012).

pubmed: 22250108

Nagino, M. et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann. Surg. 258, 129–140 (2013).

pubmed: 23059502

Ebata, T. et al. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br. J. Surg. 105, 829–838 (2018).

pubmed: 28488733

Abbas, S. & Sandroussi, C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB 15, 492–503 (2013).

pubmed: 23750491 pmcid: 3692018

de Jong, M. C. et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 118, 4737–4747 (2012).

pubmed: 22415526

Groot Koerkamp, B. et al. American joint committee on cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. HPB 16, 1074–1082 (2014).

pubmed: 25267346 pmcid: 4253330

Kizy, S. et al. Surgical resection of lymph node positive intrahepatic cholangiocarcinoma may not improve survival. HPB 21, 235–241 (2019).

pubmed: 30274882

Buettner, S. et al. Survival after resection of multiple tumor foci of intrahepatic cholangiocarcinoma. J. Gastrointest. Surg. 23, 2239–2246 (2019).

pubmed: 30887301 pmcid: 6831534

Reames, B. N. et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. J. Surg. Oncol. 116, 133–139 (2017).

pubmed: 28411373

Wang, Y. et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J. Clin. Oncol. 31, 1188–1195 (2013).

pubmed: 23358969

Wang, S. J. et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J. Clin. Oncol. 29, 4627–4632 (2011).

pubmed: 22067404 pmcid: 3236647

Zhang, X. F. et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br. J. Surg. 105, 848–856 (2018).

pubmed: 29193010

Zhang, X. F. et al. Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multi-institutional study from the US extrahepatic biliary malignancy consortium. World J. Surg. 42, 2919–2929 (2018).

pubmed: 29404753

Ebata, T. et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br. J. Surg. 105, 192–202 (2018).

pubmed: 29405274

Edeline, J. et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J. Clin. Oncol. 37, 658–667 (2019).

pubmed: 30707660

Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20, 663–673 (2019).

pubmed: 30922733

Lamarca, A. et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat. Rev. 84, 101936 (2020).

pubmed: 31986437

Shroff, R. T. et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J. Clin. Oncol. 37, 1015–1027 (2019).

pubmed: 30856044

Ben-Josef, E. et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J. Clin. Oncol. 33, 2617–2622 (2015).

pubmed: 25964250

Meyer, C. G., Penn, I. & James, L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69, 1633–1637 (2000).

pubmed: 10836374

Robles, R. et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann. Surg. 239, 265–271 (2004).

pubmed: 14745336 pmcid: 1356221

Seehofer, D. et al. Extended bile duct resection and [corrected] liver and transplantation in patients with hilar cholangiocarcinoma: long-term results. Liver Transpl. 15, 1499–1507 (2009).

pubmed: 19877250

Darwish Murad, S. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143, 88–98 e83 (2012).

pubmed: 22504095

Rea, D. J. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242, 451–458 (2005).

pubmed: 16135931 pmcid: 1357753

Sudan, D. et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am. J. Transpl. 2, 774–779 (2002).

Darwish Murad, S. et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 56, 972–981 (2012).

pubmed: 22290335

Duignan, S. et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB 16, 91–98 (2014).

pubmed: 23600750

Lehrke, H. D. et al. Prognostic significance of the histologic response of perihilar cholangiocarcinoma to preoperative neoadjuvant chemoradiation in liver explants. Am. J. Surg. Pathol. 40, 510–518 (2016).

pubmed: 26752544

Sio, T. T. et al. Outcome of transplant-fallout patients with unresectable cholangiocarcinoma. Am. J. Clin. Oncol. 39, 271–275 (2016).

pubmed: 24921218 pmcid: 4309741

Ethun, C. G. et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann. Surg. 267, 797–805 (2018).

pubmed: 29064885 pmcid: 6002861

Sapisochin, G. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann. Surg. 259, 944–952 (2014).

pubmed: 24441817

Lunsford, K. E. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol. Hepatol. 3, 337–348 (2018).

pubmed: 29548617

Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273–1281 (2010).

pubmed: 20375404

Okusaka, T. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer 103, 469–474 (2010).

pubmed: 20628385 pmcid: 2939781

Lamarca, A., Benafif, S., Ross, P., Bridgewater, J. & Valle, J. W. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: effective intervention in patients with luminal disease. Eur. J. Cancer 51, 1694–1703 (2015).

pubmed: 26066735

Shroff, R. T. et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 5, 824–830 (2019).

pubmed: 30998813 pmcid: 6567834

Sakai, D. et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer [abstract 615O]. Ann. Oncol. 29 (Suppl. 8), viii205 (2018).

McNamara, M. G. et al. A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08) [abstract 758P]. Ann. Oncol. 29 (Suppl. 8), viii259 (2018).

Lamarca, A., Hubner, R. A., David Ryder, W. & Valle, J. W. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann. Oncol. 25, 2328–2338 (2014).

pubmed: 24769639

Lamarca, A. et al. A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. [abstract ABC-06]. J. Clin. Oncol. 37 (Suppl. 15), 4003 (2019).

Lamarca, A. et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J. Natl Cancer Inst. 112, 200–210 (2020).

pubmed: 31077311

Hyder, O. et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann. Surg. Oncol. 20, 3779–3786 (2013).

pubmed: 23846786

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN, 2015).

Al-Adra, D. P. et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur. J. Surg. Oncol. 41, 120–127 (2015).

pubmed: 25449754 pmcid: 4316196

Burger, I. et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J. Vasc. Interv. Radiol. 16, 353–361 (2005).

pubmed: 15758131

Ibrahim, S. M. et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113, 2119–2128 (2008).

pubmed: 18759346

Edeline, J. T. et al. Selective internal radiation therapy (SIRT) with yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). Ann. Oncol. 28 (Suppl. 5), v209–v268 (2017).

Hong, T. S. et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 34, 460–468 (2016).

pubmed: 26668346

Cercek, A. et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6, 60–67 (2019).

pmcid: 6824231

Lowery, M. A. et al. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts [abstract]. J. Clin. Oncol. 35 (Suppl. 15), 4015 (2017).

Javle, M. M. et al. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy [abstract]. J. Clin. Oncol. 34 (Suppl. 4), 335 (2016).

Mazzaferro, V. et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) [abstract PD-019]. Ann. Oncol. 27 (Suppl. 2), ii109 (2016).

pmcid: 4984167

Liu, S. & Quarles, L. D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 18, 1637–1647 (2007).

pubmed: 17494882

Meric-Bernstam, F. et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors [abstract O-001]. Ann. Oncol. 29 (Suppl. 5), v100 (2018).

Drilon, A. et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017).

pubmed: 28183697 pmcid: 5380583

Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).

pubmed: 29466156 pmcid: 5857389

Yamamoto, K. et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer. Res. 25, 3575–3579 (2005).

pubmed: 16101182

Guo, Y. et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286 (2018).

pubmed: 29138340

Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).

pubmed: 30115704 pmcid: 30115704

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

pubmed: 4481136 pmcid: 4481136

Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318–327 (2019).

pubmed: 30557521

Marin, J. J. G. et al. Molecular bases of chemoresistance in cholangiocarcinoma. Curr. Drug Targets 18, 889–900 (2017).

pubmed: 25706108

Marin, J. J. G. et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1444–1453 (2018).

pubmed: 28600147

Fouassier, L. et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 39 (Suppl. 1), 43–62 (2019).

pubmed: 30903728

Borbath, I. et al. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur. J. Cancer 48, 990–996 (2012).

pubmed: 22137164

Martinez-Becerra, P. et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm. 9, 1693–1704 (2012).

pubmed: 22524153

Herraez, E. et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 58, 1065–1073 (2013).

pubmed: 23532667

Lautem, A. et al. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int. J. Oncol. 42, 1297–1304 (2013).

pubmed: 23440379

Al-Abdulla, R. et al. Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma. J. Hepatology 66, S462–S463 (2017).

Cao, L. et al. Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur. J. Cancer 34, 1612–1617 (1998).

pubmed: 9893638

Srimunta, U. et al. High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac. J. Cancer Prev. 13 (Suppl.), 125–130 (2012).

pubmed: 23480753

Hahnvajanawong, C. et al. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J. Gastroenterol. 18, 3955–3961 (2012).

pubmed: 22912546 pmcid: 3419992

Nakajima, T. et al. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J. Pharmacol. Exp. Ther. 306, 861–869 (2003).

pubmed: 12805482

Habara, K., Ajiki, T., Kamigaki, T., Nakamura, T. & Kuroda, Y. High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. Jpn. J. Cancer Res. 92, 1127–1132 (2001).

pubmed: 11676864 pmcid: 5926613

Marzioni, M. et al. An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Dig. Liver Dis. 44, 134–142 (2012).

pubmed: 21782536

Jimeno, A. et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 65, 3003–3010 (2005).

pubmed: 15833824

Hwang, I. G. et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemother. Pharmacol. 68, 935–944 (2011).

pubmed: 21298384

Limpaiboon, T. et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett. 217, 213–219 (2005).

pubmed: 15617839

Sato, J. et al. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 18, 700–711 (2011).

pubmed: 21451941

Wilson, T. R., Johnston, P. G. & Longley, D. B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 9, 307–319 (2009).

pubmed: 19442051

Fernandez, T. F., Samal, A. B., Bedwell, G. J., Chen, Y. & Saad, J. S. Structural and biophysical characterization of the interactions between the death domain of Fas receptor and calmodulin. J. Biol. Chem. 288, 21898–21908 (2013).

pubmed: 23760276 pmcid: 3724645

Yokoi, K. et al. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Oncol. Rep. 39, 843–850 (2018).

pubmed: 29251327

Fujita, N. et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT – correlation with clinicopathological findings. Eur. Radiol. 27, 498–506 (2017).

pubmed: 27165138

Leyva-Illades, D., McMillin, M., Quinn, M. & Demorrow, S. Cholangiocarcinoma pathogenesis: role of the tumor microenvironment. Transl. Gastrointest. Cancer 1, 71–80 (2012).

pubmed: 23002431 pmcid: 3448449

Quintavalle, C. et al. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol. Carcinog. 56, 2146–2157 (2017).

pubmed: 28467612

Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K. & Mills, E. J. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J. Clin. 70, 125–137 (2020).

pubmed: 32031692 pmcid: 7187272

Padma, V. V. An overview of targeted cancer therapy. Biomedicine 5, 19 (2015).

pubmed: 26613930 pmcid: 4662664

Maximiano, S., Magalhaes, P., Guerreiro, M. P. & Morgado, M. Trastuzumab in the treatment of breast cancer. BioDrugs 30, 75–86 (2016).

pubmed: 26892619

Geng, F., Wang, Z., Yin, H., Yu, J. & Cao, B. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother. Radiopharm. 32, 149–160 (2017).

pubmed: 28622036

Merdrignac, A. et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol. Commun. 2, 254–269 (2018).

pubmed: 29507901 pmcid: 5831019

Moirangthem, A., Wang, X., Yan, I. K. & Patel, T. Network analyses-based identification of circular ribonucleic acid-related pathways in intrahepatic cholangiocarcinoma. Tumour Biol. 40, 1010428318795761 (2018).

pubmed: 30168369

Chaisaingmongkol, J. et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57–70.e3 (2017).

pubmed: 28648284 pmcid: 5524207

Petrick, J. L. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare. PLoS One 12, e0186643 (2017).

pubmed: 5648218 pmcid: 5648218

Shin, H. R. et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 101, 579–585 (2010).

pubmed: 20085587

Jing, W. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur. J. Cancer Prev. 21, 24–31 (2012).

pubmed: 21857525

Wongjarupong, N. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 17, 149 (2017).

pubmed: 29216833 pmcid: 5721586

Ishikawa, Y., Wada, I. & Fukumoto, M. Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. J. Env. Pathol. Toxicol. Oncol. 20, 311–315 (2001).

Kato, I. & Kido, C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn. J. Cancer Res. 78, 1187–1192 (1987).

pubmed: 2826375

Kumagai, S. et al. Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers. Occup. Env. Med. 73, 545–552 (2016).

Brandi, G. et al. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control 24, 911–918 (2013).

pubmed: 23408245 pmcid: 3631123

Farioli, A. et al. Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries. Occup. Env. Med. 75, 191–198 (2018).

Ertel, A., Verghese, A., Byers, S. W., Ochs, M. & Tozeren, A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 5, 55 (2006).

pubmed: 17081305 pmcid: 17081305

Rizvi, S. et al. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget 9, 5892–5905 (2018).

pubmed: 29464042

Campbell, D. J., Dumur, C. I., Lamour, N. F., Dewitt, J. L. & Sirica, A. E. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol. Res. 42, 1119–1130 (2012).

pubmed: 22568523 pmcid: 3416930

Cadamuro, M. et al. Animal models of cholangiocarcinoma: what they teach us about the human disease. Clin. Res. Hepatol. Gastroenterol. 42, 403–415 (2018).

pubmed: 29753731

Sirica, A. E. et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47, 1178–1190 (2008).

pubmed: 18081149

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Références

Auteurs

Articles similaires

Classifications MeSH